[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fI8mtckINUYV_UShdQzjmq_c7kpoC5MVJePvJdW-YeGE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Dokuz Eylul University",[4],242,false,29,0,16532,231,[13,16,19,22,25,27,30,32],{"name":14,"count":15},"Multiple Sclerosis",14,{"name":17,"count":18},"Pain",13,{"name":20,"count":21},"Anxiety",11,{"name":23,"count":24},"Healthy",8,{"name":26,"count":24},"Fear",{"name":28,"count":29},"Pain, Acute",7,{"name":31,"count":29},"Anaesthesia",{"name":33,"count":34},"Neck Pain",6,[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,74,92,110,138,156,174,209,235,264,296,314,340,367,392,417],{"intervention":45,"totalTrials":46,"cells":47},"Remi 0.1",1,{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":72},{"trials":49,"activeCount":9},[],{"trials":51,"activeCount":9},[],{"trials":53,"activeCount":9},[],{"trials":55,"activeCount":9},[],{"trials":57,"activeCount":9},[58],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":69},"NCT02763098","Remifentanil on Hemodynamic Response to Anesthesia Induction","COMPLETED",[41],"2014-12","2015-12","2012-01",90,[68],"Anesthesia",[45,70,71],"Remi 0.2","Remi 0.3",{"trials":73,"activeCount":9},[],{"intervention":70,"totalTrials":46,"cells":75},{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":90},{"trials":77,"activeCount":9},[],{"trials":79,"activeCount":9},[],{"trials":81,"activeCount":9},[],{"trials":83,"activeCount":9},[],{"trials":85,"activeCount":9},[86],{"nctId":59,"briefTitle":60,"status":61,"phases":87,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":88,"interventions":89},[41],[68],[45,70,71],{"trials":91,"activeCount":9},[],{"intervention":71,"totalTrials":46,"cells":93},{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":108},{"trials":95,"activeCount":9},[],{"trials":97,"activeCount":9},[],{"trials":99,"activeCount":9},[],{"trials":101,"activeCount":9},[],{"trials":103,"activeCount":9},[104],{"nctId":59,"briefTitle":60,"status":61,"phases":105,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":106,"interventions":107},[41],[68],[45,70,71],{"trials":109,"activeCount":9},[],{"intervention":111,"totalTrials":46,"cells":112},"Emthexate",{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":114,"activeCount":9},[],{"trials":116,"activeCount":9},[],{"trials":118,"activeCount":9},[119],{"nctId":120,"briefTitle":121,"status":61,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT04532736","Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis",[39],"2019-03-12","2019-05-05","2017-09-02",41,[128],"Nasal Polyposis",[111,130,131],"Prednol","Mometasone Furoate",{"trials":133,"activeCount":9},[],{"trials":135,"activeCount":9},[],{"trials":137,"activeCount":9},[],{"intervention":130,"totalTrials":46,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":141,"activeCount":9},[],{"trials":143,"activeCount":9},[],{"trials":145,"activeCount":9},[146],{"nctId":120,"briefTitle":121,"status":61,"phases":147,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":148,"interventions":149},[39],[128],[111,130,131],{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[],{"intervention":131,"totalTrials":46,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":159,"activeCount":9},[],{"trials":161,"activeCount":9},[],{"trials":163,"activeCount":9},[164],{"nctId":120,"briefTitle":121,"status":61,"phases":165,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":166,"interventions":167},[39],[128],[111,130,131],{"trials":169,"activeCount":9},[],{"trials":171,"activeCount":9},[],{"trials":173,"activeCount":9},[],{"intervention":175,"totalTrials":176,"cells":177},"Voriconazole",2,{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":179,"activeCount":9},[],{"trials":181,"activeCount":9},[],{"trials":183,"activeCount":9},[],{"trials":185,"activeCount":9},[],{"trials":187,"activeCount":9},[],{"trials":189,"activeCount":9},[190,202],{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT04743544","Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy","UNKNOWN",[],"2021-12-31","2022-10-31","2019-11-01",62,[200],"Adverse Drug Reactions",[175],{"nctId":203,"briefTitle":204,"status":193,"phases":205,"primaryCompletion":195,"completion":196,"start":197,"enrollment":206,"conditions":207,"interventions":208},"NCT04547335","The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole",[],34,[200],[175],{"intervention":210,"totalTrials":46,"cells":211},"HILT & EXERCISE",{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":213,"activeCount":9},[],{"trials":215,"activeCount":9},[],{"trials":217,"activeCount":9},[],{"trials":219,"activeCount":9},[],{"trials":221,"activeCount":9},[],{"trials":223,"activeCount":9},[224],{"nctId":225,"briefTitle":226,"status":61,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT04169880","Effects of High Intensity Laser Therapy (HILT) in Patients With Subacromial Impingement Syndrome",[42],"2016-01-06","2016-05-27","2014-05-05",30,[233],"Subacromial Impingement Syndrome",[210],{"intervention":236,"totalTrials":46,"cells":237},"Intravesical Solution",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":239,"activeCount":9},[],{"trials":241,"activeCount":9},[],{"trials":243,"activeCount":9},[],{"trials":245,"activeCount":9},[],{"trials":247,"activeCount":9},[],{"trials":249,"activeCount":9},[250],{"nctId":251,"briefTitle":252,"status":193,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":263},"NCT06374914","Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients",[],"2026-04-09","2024-04-09",120,[258,259,260,261,262],"Bladder Cancer","BCG","Gemcitabine","Docetaxel","Intravesical Instillation",[236],{"intervention":265,"totalTrials":46,"cells":266},"Intravenous isotonic fluid - NaCl 131-154 mmol\u002FL in 5% dextrose",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":277},{"trials":268,"activeCount":9},[],{"trials":270,"activeCount":9},[],{"trials":272,"activeCount":9},[],{"trials":274,"activeCount":9},[],{"trials":276,"activeCount":9},[],{"trials":278,"activeCount":9},[279],{"nctId":280,"briefTitle":281,"status":61,"phases":282,"primaryCompletion":283,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":294},"NCT04781361","Comparison of the Isotonic and Hypotonic Intravenous Maintenance Fluids In Term Newborns: Neofluid Study",[],"2022-12-31","2023-06-30","2020-12-30",420,[288,289,290,291,292,293],"Newborn Complication","Hyponatremia of Newborn","Hypernatremia of Newborn","Fluid Therapy","Sodium Chloride","Isotonic Dehydration",[265,295],"Intravenous Hypotonic fluid- Sodium Chloride \u003C 130 mmol\u002FL",{"intervention":295,"totalTrials":46,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":299,"activeCount":9},[],{"trials":301,"activeCount":9},[],{"trials":303,"activeCount":9},[],{"trials":305,"activeCount":9},[],{"trials":307,"activeCount":9},[],{"trials":309,"activeCount":9},[310],{"nctId":280,"briefTitle":281,"status":61,"phases":311,"primaryCompletion":283,"completion":284,"start":285,"enrollment":286,"conditions":312,"interventions":313},[],[288,289,290,291,292,293],[265,295],{"intervention":315,"totalTrials":46,"cells":316},"amantadine sulphate",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":318,"activeCount":9},[],{"trials":320,"activeCount":9},[],{"trials":322,"activeCount":9},[],{"trials":324,"activeCount":9},[],{"trials":326,"activeCount":9},[],{"trials":328,"activeCount":9},[329],{"nctId":330,"briefTitle":331,"status":193,"phases":332,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":339},"NCT03443037","Benefits of Amantadine in Patients With Coma State",[],"2019-07-01","2016-03-01",56,[337,338],"Coma; Prolonged","Amantadine",[315],{"intervention":341,"totalTrials":46,"cells":342},"Oral care protocol",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":344,"activeCount":9},[],{"trials":346,"activeCount":9},[],{"trials":348,"activeCount":9},[],{"trials":350,"activeCount":9},[],{"trials":352,"activeCount":9},[],{"trials":354,"activeCount":9},[355],{"nctId":356,"briefTitle":357,"status":61,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":366},"NCT04586491","The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients",[42],"2020-02-10","2019-10-07",40,[363,364,365],"Mucositis","Pediatric Cancer","Oral Cavity",[341],{"intervention":368,"totalTrials":46,"cells":369},"Breastfeeding and Shotblocker",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":380},{"trials":371,"activeCount":9},[],{"trials":373,"activeCount":9},[],{"trials":375,"activeCount":9},[],{"trials":377,"activeCount":9},[],{"trials":379,"activeCount":9},[],{"trials":381,"activeCount":9},[382],{"nctId":383,"briefTitle":384,"status":61,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":391},"NCT05246787","Shotblocker and Breastfeeding on Pain\u002FComfort During Heel Lance",[42],"2022-09-20","2021-12-24",160,[28,390],"Comfort",[368],{"intervention":393,"totalTrials":46,"cells":394},"Levobupivacaine",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":396,"activeCount":9},[],{"trials":398,"activeCount":9},[],{"trials":400,"activeCount":9},[],{"trials":402,"activeCount":9},[],{"trials":404,"activeCount":9},[],{"trials":406,"activeCount":9},[407],{"nctId":408,"briefTitle":409,"status":61,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":361,"conditions":413,"interventions":415},"NCT07285759","Investigation of Antibacterial Effect of Levobupivacaine on Staphylococcus Aureus",[42],"2011-02","2010-11",[414],"Staphylococcus Aureus Bacterial Contamination",[393,416],"Fentanyl",{"intervention":416,"totalTrials":46,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":420,"activeCount":9},[],{"trials":422,"activeCount":9},[],{"trials":424,"activeCount":9},[],{"trials":426,"activeCount":9},[],{"trials":428,"activeCount":9},[],{"trials":430,"activeCount":9},[431],{"nctId":408,"briefTitle":409,"status":61,"phases":432,"primaryCompletion":411,"completion":411,"start":412,"enrollment":361,"conditions":433,"interventions":434},[42],[414],[393,416]]